Tag

Q2 2026 Results

All articles tagged with #q2 2026 results

Lilly lifts 2026 outlook on GLP-1 momentum and pipeline expansion
business2 hours ago

Lilly lifts 2026 outlook on GLP-1 momentum and pipeline expansion

Lilly reported Q2 2026 revenue of $23.0B, up 48% from a year earlier driven by Mounjaro and Zepbound, with GAAP EPS of $7.94 and non-GAAP EPS of $8.38; the company raised its full-year guidance to $85-87B in revenue and $35.50-$36.50 in non-GAAP EPS (midpoint up about $2.78) offset by $3.03 of acquired IPR&D charges, and highlighted regulatory wins (EBGLYSS for atopic dermatitis, Jaypirca in the EU for CLL) and continued obesity pipeline progress (retatrutide) with a planned BLA in 1Q 2027; Lilly also completed multiple acquisitions and announced additional investments to expand manufacturing in Indiana, underscoring a broad, growing pipeline.

Rivian trims 2026 spend, sticks to R2-driven profitability path
business5 days ago

Rivian trims 2026 spend, sticks to R2-driven profitability path

Rivian reduced its 2026 spending and narrowed its expected losses while keeping the 65,000–70,000 vehicle delivery target. In Q2, revenue rose to $1.66 billion with an adjusted loss per share of 47 cents and a gross profit of $179 million, as its software and services segment posted a profit and the R2 midsize SUV began deliveries. The company aims for profitability on a per‑unit basis with the R2 but will need more scale than 160,000 annual R2 units to achieve it. Cash stood at about $5.3 billion, with expected $1 billion in non-recourse VW debt financing and $250 million in equity from Uber this year.